Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

被引:198
作者
Song, I. S. [1 ,2 ]
Shin, H. J. [1 ,2 ]
Shim, E. J. [1 ,2 ,3 ]
Jung, I. S. [1 ,2 ]
Kim, W. Y. [1 ,2 ]
Shon, J. H. [1 ,2 ,3 ]
Shin, J. G. [1 ,2 ,3 ]
机构
[1] Inje Univ, Coll Med, Dept Pharmacol, Pusan, South Korea
[2] Inje Univ, Coll Med, Pharmacogen Res Ctr, Pusan, South Korea
[3] Inje Univ, Busan Paik Hosp, Dept Clin Pharmacol, Pusan, South Korea
关键词
D O I
10.1038/clpt.2008.61
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic variants of the organic cation transporter 2 (protein, OCT2; gene, SLC22A2) were evaluated for their contribution to the variations in the pharmacokinetics of metformin, especially to its renal elimination. Genetic variants of SLC22A2 (c. 596C> T, c. 602C> T, and c. 808G> T) showed significant differences in metformin pharmacokinetics when compared with the reference genotype, with higher peak plasma concentration (C-max) and area under the curve (AUC) and lower renal clearance (Cl-renal), thereby suggesting that a decrease in transport function associated with the SLC22A2 variants results in reduced Clrenal of metformin and consequently leads to increased plasma concentrations.
引用
收藏
页码:559 / 562
页数:4
相关论文
共 19 条
[1]   Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants [J].
Fujita, T ;
Urban, TJ ;
Leabman, MK ;
Fujita, K ;
Giacomini, KM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) :25-36
[2]  
Fukushima-Uesaka Hiromi, 2004, Drug Metab Pharmacokinet, V19, P239, DOI 10.2133/dmpk.19.239
[3]   Mechanism by which metformin reduces glucose production in type 2 diabetes [J].
Hundal, RS ;
Krssak, M ;
Dufour, S ;
Laurent, D ;
Lebon, V ;
Chandramouli, V ;
Inzucchi, SE ;
Schumann, WC ;
Petersen, KF ;
Landau, BR ;
Shulman, GI .
DIABETES, 2000, 49 (12) :2063-2069
[4]   Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population [J].
Kang, Ho-Jin ;
Song, Im-Sook ;
Shin, Ho Jung ;
Kim, Woo-Young ;
Lee, Choong-Hee ;
Shim, Joo-Cheol ;
Zhou, Hong-Hao ;
Lee, Sang Seop ;
Shin, Jae-Gook .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (04) :667-675
[5]   Metformin transport by renal basolateral organic cation transporter hOCT2 [J].
Kimura, N ;
Okuda, M ;
Inui, K .
PHARMACEUTICAL RESEARCH, 2005, 22 (02) :255-259
[6]  
Kimura Naoko, 2005, Drug Metab Pharmacokinet, V20, P379, DOI 10.2133/dmpk.20.379
[7]   Metformin hydrochloride: An antihyperglycemic agent [J].
Klepser, TB ;
Kelly, MW .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (08) :893-903
[8]   Estimating the contribution of genes and environment to variation in renal drug clearance [J].
Leabman, MK ;
Giacomini, KM .
PHARMACOGENETICS, 2003, 13 (09) :581-584
[9]   Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function [J].
Leabman, MK ;
Huang, CC ;
Kawamoto, M ;
Johns, SJ ;
Stryke, D ;
Ferrin, TE ;
DeYoung, J ;
Taylor, T ;
Clark, AG ;
Herskowitz, I ;
Giacomini, KM .
PHARMACOGENETICS, 2002, 12 (05) :395-405
[10]   PHARMACOKINETIC OPTIMIZATION OF ORAL HYPOGLYCEMIC THERAPY [J].
MARCHETTI, P ;
GIANNARELLI, R ;
DICARLO, A ;
NAVALESI, R .
CLINICAL PHARMACOKINETICS, 1991, 21 (04) :308-317